Suzhou Suncadia Biopharmaceuticals Co., Ltd.
PharmaSuzhou, Jiangsu, China · Est. 2010
Suzhou Suncadia Biopharmaceuticals is a Chinese biopharmaceutical company focused on developing innovative drugs for oncology and other therapeutic areas.
28
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
26
Indications↗
Distinct diseases across all programs
98
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
28 drugs in development
Phase 312
Phase 29
Phase 15
Preclinical3
By Therapeutic Area
top 4
Oncology
2790%
Musculoskeletal
13%
Immunology
13%
Nephrology
13%
R&D Momentum
80/100
Pipeline Velocity
56/100
Trial Completion Rate
58/100
Pipeline Concentration
81/100
Pipeline Freshness
82/100
Strategic Signals
- ↗Active in Musculoskeletal but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Recruiting
A Randomized, Open, Multicenter Phase II/III Clinical Study of SHR-A2102 for Injection Combined With Adebrelimab (SHR-1316) in Perioperative Treatment of Muscular Invasive Bladder Cancer (MIBC)
Jul 2, 2026
Recruiting
A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jul 1, 2026
Recruiting
A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Jul 1, 2026
Active, not recruiting
An Open Label, Multicenter Phase I Clinical Study on the Pharmacokinetics, Safety, Tolerability, and Efficacy of SHR-1316 (SC) Combined With Carboplatin and Etoposide in First-line Treatment of Extensive Stage Small Cell Lung Cancer
Earlier
Jun 24, 2026TrialAn Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-3079 Injection in Participants With B-Cell Non-Hodgkin Lymphoma
Apr 1, 2026TrialA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Mar 16, 2026TrialA Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects
Details
Company Info
Therapeutic Focus
oncologyimmunologyrare diseases
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology(1 drug)
—
—
1
1
—
Immunology(1 drug)
Musculoskeletal(1 drug)
—
—
—
1
—
Musculoskeletal(1 drug)
Nephrology(1 drug)
—
—
1
—
—
Nephrology(1 drug)
Oncology(27 drugs)
3
5
11
12
—
Oncology(27 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)